Advanced Filters
noise

Paris Cedex 20, France Clinical Trials

A listing of Paris Cedex 20, France clinical trials actively recruiting patients volunteers.

Found 1,494 clinical trials
O Odile LAUNAY, MD

Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine

This study is to evaluate the long-term immunogenicity of a boost dose of MVA-BN vaccine

18 years of age All Phase N/A
M Martin Dres, MD phD

Incidence and Impact of ICU-acquired Diaphragm Weakness

ICU survivors are at an increased risk of hospital and ICU readmission. Among the complications of ICU stay, diaphragmatic dysfunction is common, with a prevalence of 60 to 80%, and is associated with increased mortality and prolonged hospital stays. Furthermore, several studies have reported that the observation of impaired respiratory …

18 years of age All Phase N/A
E Emmenuelle VIDAL PETIOT

A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort

This registry aims to provide the first prospective, multicentric database of patients with malignant hypertension. It will allow to assess modern epidemiology of the disease, diversity of current management and care pathway, to deepen our pathophysiological knowledges, to modernize the definition of this form of hypertension and its diagnostic criteria. …

18 years of age All Phase N/A
J Julien Burel

Liquid Biopsies for the Detection of Somatic Mutations in bAVMs

"Personalized medicine has revolutionized patient care, particularly in oncology. Brain arteriovenous malformations (bAVMs) are abnormal vessels located on the surface of the brain or within the brain parenchyma, causing abnormal communication between arterial and venous networks, without the interposition of the capillary bed. The main risk of these malformations is …

18 years of age All Phase N/A
S Sonia Gueguen, PHD

National Cohort on Congenital Defects of the Eye

Congenital malformations of the eye comprise various developmental defects including microphthalmia, anophthalmia, aniridia, and anterior segment anomalies (such as Peters and Axenfeld-Rieger anomalies). These malformations are frequently associated with extra-ocular features and intellectual disability. However, little is known about visual outcome, frequency and consequences of extra-ocular features in patients. The …

years of age All Phase N/A
D Damien BODET, MD

Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults

It involves collecting safety and efficacy data, under the actual conditions of use of medicines in children and adolescents, using a validated tool (Ennov EDC) and relying on the network of Interregional pediatric oncology appeal organizations (OIR) identified by INCa since 2010 and responsible for the organization of Pluridisciplinary Pediatric …

- 25 years of age All Phase N/A
C Corinne GUITTON, MD

Pathophysiological Explorations of Red Blood Cells

GR-Ex is a program labelled by Labex (Laboratory of Excellence) by the French Ministry of Higher Education and Research. This program aims to develop the means to improve knowledge in the physiology and pathologies of erythropoiesis, red blood cells and iron metabolism, and to develop new therapeutic protocols capable of …

years of age All Phase N/A

FARD (RaDiCo Cohort) (RaDiCo-FARD)

The goal of this observational study is to conduct a prospective assessment of the individual Burden of 9 rare skin diseases to assess disability in the broadest sense of the term (psychological, social, economic and physical) for patients and/or families. Two types of indicators will be used to reach this …

years of age All Phase N/A

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.

years of age All Phase N/A

FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy

The aim of this study is to assess the clinical outcomes in real-life setting of early breast cancer RH+ HER2- patients with systemic therapy guided by Oncotype DX (ODX) Breast Recurrence Score®.

18 years of age Female Phase N/A

Simplify language using AI